Fibronectin and T Lymphocyte Growth in Cancer Patients
Author Information
Author(s): S Mizobata, H Tanimura, H Yamaue, M Tani, T Tsunoda, M Iwahashi, K Noguchi, N Nishimoto, T Hotta, K Arii
Primary Institution: Wakayama Medical School
Hypothesis
Does fibronectin enhance the activity of cytotoxic T lymphocytes generated from cancer patients?
Conclusion
Fibronectin significantly enhances the proliferation and cytotoxic activity of T lymphocytes in cancer patients.
Supporting Evidence
- Fibronectin increased the proliferation of T lymphocytes by three to four times.
- CTLs stimulated by fibronectin showed significantly higher cytotoxic activity against autologous tumor cells.
- Production of cytokines like IL-2 and IFN-y was significantly increased with fibronectin stimulation.
Takeaway
Fibronectin helps special immune cells called T lymphocytes grow and fight cancer better.
Methodology
The study involved obtaining peripheral blood mononuclear cells from cancer patients and stimulating them with immobilized anti-CD3 monoclonal antibody and interleukin 2, with and without fibronectin.
Participant Demographics
Patients with various types of malignant diseases including thyroid, gastric, duodenal, colonic, gallbladder cancers, and others.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website